Thyroid Cancer

Thyroid cancer refers to neoplastic growths arising from the thyroid gland, a bilobed endocrine organ located in the ventral cervical region adjacent to the trachea. The thyroid gland is responsible for producing thyroid hormones, primarily thyroxine and triiodothyronine, which regulate metabolic rate, growth, development, and numerous physiological processes throughout the body. Thyroid tumors account for approximately 1 to 4 percent of all neoplasms in dogs and represent the most common endocrine tumor in canines.

Thyroid tumors in dogs are classified into two major categories: adenomas and carcinomas. Thyroid adenomas are benign tumors that are typically small, well-encapsulated, and non-invasive. They are relatively uncommon as clinically detected masses in dogs, though they are occasionally found incidentally during necropsy. Thyroid carcinomas, in contrast, are malignant tumors that constitute the majority of clinically significant thyroid neoplasms in dogs, accounting for approximately 90 percent of thyroid tumors that are diagnosed during the patient's lifetime.

Thyroid carcinomas are further subclassified based on their histological pattern into follicular, compact or solid, papillary, and mixed types. Follicular carcinomas arise from the hormone-producing follicular epithelial cells and are the most common subtype. Compact carcinomas are composed of solid sheets of cells without follicular architecture. Medullary thyroid carcinomas, which originate from the parafollicular C-cells that produce calcitonin, are recognized in dogs but are considerably less common than follicular-derived tumors.

The biological behavior of thyroid carcinomas in dogs is highly variable. Some tumors remain relatively localized and are amenable to surgical excision with good long-term outcomes, while others are highly invasive into surrounding structures and metastasize readily to regional lymph nodes and the lungs. The tumor's size, invasiveness, histological subtype, and functional status all influence its clinical behavior and the approach to treatment planning.

The precise etiology of thyroid cancer in dogs remains incompletely understood, though several risk factors have been identified through epidemiological studies and clinical observation. Unlike in humans, where radiation exposure and iodine deficiency are well-established risk factors for thyroid malignancy, the relationship between these factors and canine thyroid cancer is less clearly defined. However, experimental studies have demonstrated that prolonged thyroid-stimulating hormone elevation, whether from iodine deficiency, goitrogenic compounds, or other causes, can promote thyroid cell proliferation and potentially increase the risk of neoplastic transformation.

Breed predispositions provide evidence for a genetic component in the development of thyroid cancer. Boxers, Beagles, and Golden Retrievers are consistently identified as breeds with increased risk. Siberian Huskies, German Shepherds, and several other medium to large breeds also appear to be overrepresented in clinical studies. The specific genetic mutations or hereditary factors responsible for these breed predispositions have not been fully elucidated, though research into somatic mutations affecting oncogenes and tumor suppressor genes in canine thyroid carcinomas is ongoing.

Age is a significant risk factor, with thyroid cancer most commonly diagnosed in middle-aged to older dogs, typically between 9 and 12 years of age. There does not appear to be a strong sex predilection, though some studies have suggested a slight overrepresentation in male dogs or in spayed females, with findings varying across study populations. Dogs with a history of hypothyroidism requiring supplementation do not appear to have an elevated risk of thyroid cancer, and the relationship between preexisting thyroid disease and subsequent tumor development remains an area of ongoing investigation.

Environmental exposures have been explored as potential contributing factors. Some researchers have hypothesized that chronic exposure to environmental endocrine disruptors, pesticides, or industrial chemicals may influence thyroid carcinogenesis in companion animals, paralleling concerns in human medicine. Polybrominated diphenyl ethers and other persistent organic pollutants that accumulate in household dust and pet food have received particular attention, though definitive causal relationships have not been established in canine populations.

The most common clinical presentation of thyroid cancer in dogs is a palpable mass in the ventral cervical region, typically discovered by the owner or identified during routine veterinary examination. The mass may be unilateral or, less commonly, bilateral, as the thyroid gland consists of two separate lobes. Thyroid masses can vary considerably in size at the time of diagnosis, ranging from small nodules of less than two centimeters to large masses exceeding ten centimeters that distort the normal cervical anatomy.

As the tumor enlarges, it may produce signs related to compression or invasion of adjacent structures. Dysphagia, or difficulty swallowing, can occur when the mass impinges on the esophagus. Dyspnea and changes in respiratory pattern may develop if the trachea is compressed or displaced. Voice changes, characterized by an altered bark, can result from involvement of the recurrent laryngeal nerve. Some dogs develop facial or cervical edema if the tumor compresses or invades the jugular veins, impairing venous drainage from the head.

Approximately 30 to 40 percent of dogs with thyroid carcinoma have detectable pulmonary metastases at the time of diagnosis, and some patients present with clinical signs attributable to metastatic disease rather than the primary tumor. Coughing, exercise intolerance, and respiratory distress may indicate pulmonary involvement. Less commonly, metastasis to regional cervical lymph nodes, bone, liver, kidneys, or adrenal glands may produce signs referable to those organs.

The majority of thyroid tumors in dogs are nonfunctional, meaning they do not produce excess thyroid hormones. However, approximately 10 to 20 percent of thyroid carcinomas are functional and secrete thyroid hormones autonomously, leading to clinical hyperthyroidism. Signs of hyperthyroidism in dogs include weight loss despite a normal or increased appetite, polyuria and polydipsia, tachycardia, restlessness, panting, muscle wasting, and heat intolerance. Some dogs present with hypothyroidism if the tumor has destroyed sufficient normal thyroid tissue without producing adequate hormone itself.

The diagnostic evaluation of a suspected thyroid tumor begins with a thorough physical examination including careful palpation of the ventral cervical region. The veterinarian assesses the size, shape, consistency, and mobility of the mass, as these characteristics provide important initial information about the likely tumor type and invasiveness. Freely movable masses are more likely to be amenable to surgical excision, while fixed or adherent masses suggest local invasion into surrounding tissues and present greater surgical challenges.

Advanced imaging is a critical component of the diagnostic workup. Cervical ultrasonography is typically the first-line imaging modality, providing detailed information about the mass's size, echogenicity, vascularity, and relationship to adjacent structures including the carotid artery, jugular vein, trachea, and esophagus. Computed tomography of the cervical region and thorax is recommended for comprehensive staging, offering superior anatomical detail for surgical planning and enabling detection of pulmonary metastases, mediastinal lymphadenopathy, and vascular invasion that may not be apparent on radiographs or ultrasound.

Fine-needle aspiration cytology of the thyroid mass can provide preliminary diagnostic information and may be sufficient to differentiate thyroid neoplasia from other cervical masses such as salivary gland tumors, lymphoma, or abscesses. However, cytology alone cannot reliably distinguish between thyroid adenoma and carcinoma or determine the histological subtype, and definitive diagnosis typically requires histopathological examination of tissue obtained through incisional biopsy or following surgical excision. Care must be taken during aspiration due to the highly vascular nature of thyroid tumors and their proximity to major blood vessels.

Thyroid function testing is important for determining whether the tumor is functional. Measurement of total thyroxine, free thyroxine, and thyroid-stimulating hormone levels helps identify dogs with functional tumors producing excess hormones as well as those with hypothyroidism from destruction of normal thyroid tissue. Thyroid scintigraphy using technetium-99m pertechnetate or radioactive iodine-123 is valuable for assessing the functional status of the tumor, identifying ectopic thyroid tissue, detecting bilateral involvement, and evaluating for metastatic disease. This nuclear medicine technique also helps determine eligibility for radioactive iodine therapy.

Accurate staging of thyroid cancer is essential for treatment planning and prognostic assessment. The World Health Organization staging system for canine thyroid tumors classifies the disease based on tumor size, invasiveness, lymph node involvement, and the presence of distant metastases. Stage I tumors are less than two centimeters in maximum diameter and are confined to the thyroid gland without evidence of invasion. Stage II tumors measure two to five centimeters and may show minimal local invasion. Stage III tumors exceed five centimeters or demonstrate significant invasion into adjacent structures. Stage IV disease involves regional lymph node metastasis or distant metastatic spread.

The tumor's relationship to surrounding vascular structures is a particularly important aspect of staging and surgical planning. Thyroid carcinomas frequently invade or encapsulate the carotid artery, with the degree of vascular involvement directly impacting surgical resectability. Tumors that are freely movable and separable from vascular structures carry the best surgical prognosis, while those with circumferential vascular encasement may be deemed inoperable. Cross-sectional imaging with contrast-enhanced computed tomography or magnetic resonance imaging provides the most accurate preoperative assessment of vascular invasion.

Histological grading provides additional prognostic information beyond clinical staging. Well-differentiated follicular carcinomas that retain recognizable thyroid architecture generally carry a more favorable prognosis than poorly differentiated or anaplastic tumors. The mitotic index, measured as the number of mitotic figures per high-power field, correlates with tumor aggressiveness, with higher mitotic counts associated with greater metastatic potential and shorter survival times. Vascular and lymphatic invasion identified on histopathology are negative prognostic indicators that increase the likelihood of distant metastatic spread.

Complete staging requires thorough evaluation for metastatic disease. Three-view thoracic radiographs or thoracic computed tomography should be performed to evaluate the lungs, which are the most common site of distant metastasis. Abdominal ultrasonography assesses the liver, spleen, kidneys, and abdominal lymph nodes for evidence of metastatic involvement. Regional cervical and retropharyngeal lymph nodes should be evaluated through palpation, imaging, and fine-needle aspiration cytology when enlarged. The staging workup collectively enables the veterinary oncologist to develop a comprehensive treatment plan tailored to the individual patient's disease extent.

Surgical thyroidectomy is considered the primary treatment modality for canine thyroid tumors that are freely movable and can be completely excised with adequate margins. The surgical approach involves careful dissection of the thyroid mass from the surrounding cervical structures, with particular attention to preserving the recurrent laryngeal nerves, parathyroid glands, and major blood vessels when possible. Unilateral thyroidectomy is performed for tumors confined to one lobe, while bilateral thyroidectomy may be necessary for tumors involving both lobes, though this procedure carries a higher risk of postoperative complications.

The success of surgical treatment depends heavily on the ability to achieve complete excision with clean histological margins. Freely movable thyroid tumors that can be cleanly separated from surrounding structures carry the most favorable surgical outcomes, with reported median survival times ranging from approximately 24 to 36 months or longer in some studies. Tumors that are adherent to or invasive of surrounding structures are associated with higher rates of incomplete excision and correspondingly shorter survival times. The involvement of the carotid artery or jugular vein can make complete surgical resection extremely challenging or impossible.

Postoperative complications of thyroidectomy include hemorrhage, seroma formation, wound infection, damage to the recurrent laryngeal nerves causing laryngeal paralysis, and hypoparathyroidism resulting from inadvertent removal of or damage to the parathyroid glands. Hypoparathyroidism leads to hypocalcemia, which can cause muscle tremors, facial rubbing, seizures, and potentially life-threatening cardiac arrhythmias. Postoperative calcium monitoring is essential, particularly following bilateral thyroidectomy. Thyroid hormone supplementation is typically required following total thyroidectomy and may be needed after unilateral procedures depending on the function of the remaining thyroid tissue.

Debulking surgery, in which a portion of the tumor is removed without achieving complete margins, may be considered for large or invasive tumors to relieve compression of the trachea or esophagus and improve quality of life. Debulking is often combined with adjuvant radiation therapy or radioactive iodine treatment to address residual disease. While not curative, this combined approach can provide meaningful palliation and extend survival in dogs with otherwise inoperable tumors.

External beam radiation therapy plays an important role in the management of canine thyroid carcinoma, particularly for tumors that are not amenable to complete surgical excision. Radiation therapy may be used as the primary treatment modality for invasive, fixed tumors, as adjuvant therapy following incomplete surgical excision to control residual microscopic disease, or as a palliative measure to slow tumor progression and relieve clinical signs. Definitive radiation protocols typically involve multiple fractions delivered over several weeks, while palliative protocols use fewer, larger fractions over a shorter treatment course.

Radioactive iodine therapy using iodine-131 represents a unique and highly effective treatment option for thyroid carcinomas that retain the ability to concentrate iodine. This form of targeted radionuclide therapy delivers high doses of radiation directly to functional thyroid tumor cells and their metastases while sparing surrounding normal tissues. The treatment involves a single intravenous injection of radioactive iodine, which is selectively taken up by iodine-avid thyroid tissue. Dogs must be hospitalized in a radiation isolation facility until their residual radioactivity decreases to safe levels, typically for one to two weeks.

Pretreatment thyroid scintigraphy is essential to determine whether a thyroid tumor is a candidate for radioactive iodine therapy. Tumors that demonstrate uptake of technetium-99m pertechnetate or iodine-123 on scintigraphy are considered iodine-avid and likely to respond to iodine-131 treatment. Approximately 60 to 70 percent of canine thyroid carcinomas demonstrate sufficient iodine uptake to be candidates for this therapy. Withdrawal of thyroid hormone supplementation prior to scintigraphy and treatment can enhance iodine uptake by increasing endogenous thyroid-stimulating hormone levels.

Response rates to radioactive iodine therapy in appropriate candidates are encouraging, with many dogs achieving significant tumor regression or stabilization of disease. Some studies have reported median survival times exceeding three years in dogs treated with radioactive iodine, particularly those with well-differentiated, iodine-avid tumors without extensive metastatic disease at the time of treatment. Potential side effects include transient bone marrow suppression, gastrointestinal disturbances, and radiation thyroiditis causing temporary neck swelling and discomfort. Hypothyroidism is an expected consequence of successful treatment and is easily managed with oral thyroid hormone supplementation.

Chemotherapy may be considered for dogs with thyroid carcinoma that has metastasized, for tumors that are not candidates for surgery or radiation therapy, or as adjuvant treatment following surgery to reduce the risk of metastatic progression. Doxorubicin is the most commonly studied chemotherapy agent for canine thyroid carcinoma, with reported response rates varying across studies. The drug is administered intravenously every three weeks for a series of treatments, with careful monitoring for cumulative cardiotoxicity, which is the dose-limiting side effect of doxorubicin.

Cisplatin and carboplatin, platinum-based chemotherapy agents, have also been used in the treatment of canine thyroid carcinoma either as single agents or in combination protocols. While response rates to platinum drugs have been variable, some dogs demonstrate meaningful tumor regression or stabilization. Toceranib phosphate, a multi-targeted receptor tyrosine kinase inhibitor approved for use in dogs, has shown activity against thyroid carcinomas and may be considered for cases that are refractory to conventional chemotherapy or for long-term maintenance therapy following initial treatment.

Medical management of functional thyroid carcinomas producing excess thyroid hormones requires control of hyperthyroidism to manage clinical signs and reduce the metabolic stress on the cardiovascular system. Methimazole, an antithyroid medication that inhibits thyroid hormone synthesis, can be used to control hyperthyroidism while definitive treatment is planned. Beta-adrenergic blocking agents may be prescribed to manage tachycardia and other cardiovascular effects of excess thyroid hormone until the hormone levels are brought under control.

Palliative and supportive care is an important component of management for dogs with advanced or end-stage thyroid cancer. Pain management using nonsteroidal anti-inflammatory drugs, opioids, or other analgesics addresses discomfort from the primary tumor or metastatic sites. Nutritional support, including appetite stimulants and dietary modifications, helps maintain body condition in dogs with cancer-related cachexia. Anti-nausea medications may be needed to manage gastrointestinal side effects of chemotherapy. The overarching goal of medical management in advanced disease is to maintain the best possible quality of life for the patient while respecting the owner's values and wishes regarding the extent of treatment.

The prognosis for dogs with thyroid cancer varies considerably based on tumor type, size, invasiveness, histological grade, metastatic status, and the treatment modality employed. Thyroid adenomas, being benign, carry an excellent prognosis following complete surgical excision, with cure expected in virtually all cases. The prognosis for thyroid carcinomas is more variable and depends on the specific characteristics of each individual case.

For freely movable thyroid carcinomas treated with complete surgical excision, reported median survival times generally range from two to three years, with many dogs surviving significantly longer. Dogs with small, well-differentiated, completely excised tumors without metastatic disease at diagnosis have the most favorable outlook. The one-year and two-year survival rates for dogs with surgically resectable tumors are approximately 75 to 80 percent and 50 to 65 percent, respectively, in published studies, though outcomes vary across institutions.

Invasive, fixed thyroid carcinomas that cannot be completely excised carry a less favorable prognosis, with median survival times generally ranging from 6 to 12 months with conventional treatment. However, multimodal therapy combining debulking surgery with radiation therapy or radioactive iodine treatment can significantly improve outcomes for some of these patients. Dogs with pulmonary metastases at the time of diagnosis have a more guarded prognosis, though some dogs with limited metastatic disease and iodine-avid tumors can achieve prolonged survival with radioactive iodine therapy.

Prognostic factors that have been consistently associated with outcome include tumor volume, with smaller tumors carrying a better prognosis; bilateral versus unilateral involvement, with bilateral disease associated with worse outcomes; the presence or absence of vascular invasion on histopathology; mitotic rate; completeness of surgical excision; and the tumor's functional and iodine-uptake status. The ability to concentrate iodine is a favorable prognostic indicator because it opens the door to radioactive iodine therapy, which has produced some of the longest survival times reported for canine thyroid carcinoma.

Caring for a dog diagnosed with thyroid cancer requires a comprehensive approach that addresses the medical, nutritional, and emotional needs of both the patient and the owner. Following the initial diagnosis and staging, owners should have a thorough discussion with the veterinary oncologist about the available treatment options, expected outcomes, potential side effects, financial considerations, and quality-of-life implications. Understanding the goals of treatment, whether curative or palliative, helps owners make informed decisions and set realistic expectations.

Postoperative care following thyroidectomy includes wound management, activity restriction during healing, administration of prescribed medications including pain management and thyroid hormone supplementation, and monitoring for complications such as hypocalcemia. Owners should be familiar with the signs of hypocalcemia, which include muscle tremors, twitching of the facial muscles, stiff gait, restlessness, and seizures, and understand that this complication requires immediate veterinary attention. Regular blood work to monitor calcium and thyroid hormone levels is essential during the postoperative period.

Dogs receiving chemotherapy require regular monitoring and supportive care between treatment sessions. Owners should be aware of the expected side effects, which may include decreased appetite, mild gastrointestinal disturbances, lethargy for a few days following treatment, and potential for immunosuppression increasing susceptibility to infections. Temperature monitoring at home and prompt reporting of fever, persistent vomiting, diarrhea, or other concerning signs helps ensure timely intervention if complications develop.

Quality of life assessment is a continuous process throughout the course of treatment for thyroid cancer. Veterinary oncologists and general practitioners can provide structured quality-of-life scales that help owners objectively evaluate their dog's wellbeing across domains including pain, appetite, hydration, mobility, hygiene, social interaction, and overall happiness. Regular reassessment ensures that treatment decisions continue to align with the goal of maintaining a good quality of life. When treatment is no longer providing benefit or when quality of life declines despite intervention, compassionate end-of-life planning, including palliative care and humane euthanasia when appropriate, should be discussed openly and supportively with the veterinary team.